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potentially effective therapeutic strategy for lung cancer
because of its high gene-silencing effects and sequence
speciﬁcity. Previous studies reported that intratracheal admin-
istration of siRNA using pressurized metered dose inhalers or
nebulizers could suppress tumor growth in murine lung met-
astatic models. Although dry powder inhalers are promising
devices due to their low cost, good portability, and preserv-
ability, the anti-tumor effects of siRNA dry powder have not
been elucidated. To evaluate the gene-silencing and anti-tu-
mor effects of intratracheally delivered siRNA dry powder,
vascular endothelial growth factor-speciﬁc siRNA (VEGF-
siRNA) dry powder was administered intratracheally to mice
with metastatic lung tumors consisting of B16F10 melanoma
cells or Lewis lung carcinoma cells. A single intratracheal
administration of VEGF-siRNA dry powder reduced VEGF
levels in both bronchoalveolar lavage ﬂuid and lung tumor
tissue. Furthermore, repeated intratracheal administration of
VEGF-siRNA dry powder suppressed the number of visible
metastatic foci on the lung surface and tumor area in lung
tissues. Taken together, intratracheal administration of siRNA
dry powder could be a novel therapeutic strategy for lung
cancer through the suppression of speciﬁc genes expressed
in lung tumor tissue.Received 13 March 2018; accepted 13 July 2018;
https://doi.org/10.1016/j.omtn.2018.07.009.
5These authors contributed equally to this work.
Correspondence: Professor Noboru Hattori, MD, PhD, Department of Molecular
and Internal Medicine, Graduate School of Biomedical & Health Sciences,
Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
E-mail: nhattori@hiroshima-u.ac.jpINTRODUCTION
RNA interference using small interfering RNA (siRNA) is a mecha-
nism of silencing gene expression that results in sequence-speciﬁc
mRNA degradation.1 Because of its high gene-silencing effect,
sequence speciﬁcity, and adjustability for targeting any disease-pro-
moting gene, siRNA could apply to the treatment of intractable
diseases, including cancer. For the clinical application of siRNA, an
efﬁcient delivery method to target cells is essential. With direct acces-
sibility through the airways, the lung is an attractive target organ for
siRNA delivery using inhalation systems.698 Molecular Therapy: Nucleic Acids Vol. 12 September 2018 ª 2018
This is an open access article under the CC BY-NC-ND license (httpThree types of inhalation systems are available: pressurized metered
dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs).
Although MDIs are commonly used inhalers, the required propel-
lants, such as chloroﬂuorocarbons or hydroﬂuoroalkanes, are unfa-
vorable to the environment.2,3 Nebulizers are also commonly used;
however, they are not suitable for long-term storage, as nucleic acids
are unstable during the process of liquid formation.4 On the con-
trary, DPIs present several advantages, as they do not require
propellants and have good preservability, low cost, and good porta-
bility.5,6 Thus, DPIs are the most suitable type of inhalation device
for siRNA delivery. In our previous study, we demonstrated that
intratracheal administration of siRNA dry powder with water-solu-
ble chitosan as a non-viral vector produced by the supercritical
carbon dioxide technique could suppress gene expression, not
only in airways including the bronchus, bronchiole, and alveolus,
but also inside lung tumors.7 This result indicated that intratracheal
administration of siRNA could have therapeutic potential for lung
cancer through the suppression of speciﬁc genes expressed in
lung tumors. Several previous studies reported that intratracheal
administration of RNA interference agents exerted an anti-tumor
effect in murine lung metastasis models when administered using
MDIs or nebulizers.8–10 However, the anti-tumor effect of intratra-
cheal administration of siRNA dry powder on lung tumors is not
known.
Spray-freeze-drying (SFD) is a novel powderization technique used to
produce a highly porous low-density powder, with high dispersibility
and reachability to the lungs.11 Mohri et al.12 reported thatThe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Evaluation of Gene-Silencing Effect of
VEGF-siRNA In Vitro
(A and C) B16F10 cells and (B and D) LLC cells were
treated with VEGF-siRNA, non-target siRNA, or trans-
fection reagent alone. (A and B) Concentrations of VEGF
protein in culture supernatant fluid obtained from B16F10
(A) or LLC (B) cells were measured by enzyme-linked
immunosorbent assay (n = 8/group). (C and D) VEGF-A
mRNA levels in the cells obtained from B16F10 (C) or LLC
(D) cells normalized to beta-actin levels were quantified by
real-time RT-PCR (n = 3–4/group). p was determined
using the Wilcoxon rank-sum test. *p < 0.05, **p < 0.01
between two groups. N.S., not significant. Bars denote
the median values.
www.moleculartherapy.orgintratracheal administration of plasmid DNA dry powder produced
by SFD could reach to intrapulmonary region and exhibit gene
expression in the lungs. However, the gene-silencing effect of intratra-
cheal administration of siRNA dry powder produced by SFD has not
been elucidated.
Vascular endothelial growth factor (VEGF) stimulates neovasculari-
zation and strongly contributes to cancer progression. Inhibiting neo-
vascularization by bevacizumab, a humanized monoclonal antibody
against VEGF, has shown clinical effectiveness in various cancers,
including lung cancer.13–15 Moreover, a previous study reported
that local injection of VEGF-speciﬁc-siRNA (VEGF-siRNA) could
inhibit tumor growth in a murine subcutaneous tumor model.16Molecular TherapThus, pulmonary administration of VEGF-
siRNA could be an effective therapeutic strategy
to treat lung cancer when efﬁciently delivered to
lung tumors.
The objective of this study was to investigate the
gene-speciﬁc suppressive effects of the intratra-
cheal administration of a novel VEGF-siRNA
and chitosan dry powder produced by SFD on
lung tumors and assess its inhibitory effect on
tumor growth in a murine lung metastasis
model.
RESULTS
Effect of VEGF Gene-Specific Knockdown
by VEGF-siRNA In Vitro
To conﬁrm the gene-speciﬁc suppression of
VEGF by VEGF-siRNA, VEGF-siRNA was
transfected in two cancer cell lines (B16F10
and Lewis lung carcinoma [LLC]). In both
cell lines, total VEGF protein in culture
supernatant ﬂuid and relative VEGF mRNA
expression levels in the cells obtained from
VEGF-siRNA-treated cells were signiﬁcantly
decreased compared with those obtained fromcells treated with non-target siRNA or transfection reagent alone
(Figures 1A–1D).
Suppression of VEGF Expression in Lung Tumor with a Single
Intratracheal Administration of VEGF-siRNA and Chitosan Dry
Powder
Next, we examined whether intratracheal administration of VEGF-
siRNA dry powder could reduce VEGF expression in lung tumor
tissue. We used water-soluble chitosan as a non-viral vector. As a
preliminary experiment, we monitored VEGF protein levels in
bronchoalveolar lavage ﬂuid (BALF) obtained from tumor-bearing
mice; the VEGF amount in BALF was signiﬁcantly increased
18 days after B16F10 injection and 14 days after LLC injection.y: Nucleic Acids Vol. 12 September 2018 699
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Figure 2. Evaluation of Gene-Silencing Effect of
VEGF-siRNA Dry Power In Vivo
(A and B) B16F10 tumor-bearing mice (n = 6–8/group) or
(C and D) LLC tumor-bearing mice (n = 8/group) were
treated with a single administration of VEGF-siRNA dry
powder or non-target siRNA dry powder. After 48 hr,
bronchoalveolar lavage fluid samples were obtained from
all subjects, and lungs were harvested. Same-aged,
non-tumor-bearing mice served as controls (n = 5).
(A and C) Concentrations of VEGF protein in bron-
choalveolar lavage fluid obtained from B16F10 (A) or LLC
(C) tumor-bearing mice were measured by ELISA. Bars
denote the median values. (B and D) Representative
images of immunohistochemical stainings of VEGF in
lung tumors obtained from B16F10 (B) or LLC (D) tumor-
bearing mice. Scale bar, 100 mm. p was determined
using the Wilcoxon rank-sum test. *p < 0.05, **p < 0.01
between two groups.
Molecular Therapy: Nucleic AcidsIn tumor-bearing mice treated with VEGF-siRNA, the VEGF
amount in BALF was signiﬁcantly decreased compared with that
of tumor-bearing mice treated with non-target siRNA and resem-
bled that of non-tumor-bearing mice (Figures 2A and 2C). Further-
more, immunohistochemical staining of excised lung tumor sec-
tions using an anti-VEGF antibody conﬁrmed the suppression of
VEGF in lung tumor tissue obtained from tumor-bearing mice
treated with VEGF-siRNA (Figures 2B and 2D). These results
revealed that even a single intratracheal administration of VEGF-
siRNA dry powder sufﬁciently suppressed VEGF expression in
lung tumors.
Repeated Intratracheal Administration of VEGF-siRNA and
Chitosan Dry Powder Inhibited Tumor Growth in the Lung
On the basis of the knockdown effect observed in lung tumor
tissue with a single intratracheal administration of VEGF-siRNA,
we examined whether repeated intratracheal administration of
VEGF-siRNA dry powder could inhibit tumor growth in the
lung. First, we examined the anti-tumor effect in mice carrying
metastatic lung tumors consisting of B16F10 melanoma cells. As
a preliminary experiment, we monitored visible tumors on the
lung surface in tumor-bearing mice. Lung tumors were visible after
4 days and reached an evaluable tumor burden 18 days after700 Molecular Therapy: Nucleic Acids Vol. 12 September 2018B16F10 injection. In the VEGF-siRNA group,
the number of visible foci was signiﬁcantly
reduced compared with that in the non-
target-siRNA group or no siRNA group (Fig-
ures 3A and 3B). Moreover, the percentage of
lung tumor area in the VEGF-siRNA group
was also signiﬁcantly reduced compared
with that in the non-target-siRNA group or
no siRNA group in histological examinations
(Figures 3C and 3D). Additionally, there was
no remarkable toxicity, such as body weight
loss (Figure 4A) or inﬂammatory changein lung sections from mice treated with VEGF-siRNA (Figures
4B–4E).
Next, we examined the anti-tumor effect in mice carrying metastatic
lung tumors consisting of LLC cells. According to a preliminary
experiment, similar to B16F10 melanoma cells, tumors were visible
on the lung surface 4 days after injection. However, some mice died
on day 18 due to rapid tumor progression. Therefore, we optimized
the time course as described in the Materials and Methods section.
The number of visible foci and lung tumor area were signiﬁcantly
reduced compared with that in the non-target siRNA group (Figures
5A–5D).
In Vitro Inhalation Characteristics of VEGF-siRNA and Chitosan
Dry Powders
Figure 6 shows the morphology of particles prepared using the SFD
technique. Both powder particles with VEGF-siRNA and non-target
siRNA had a geometric diameter of around 10 mm. Because of their
high porosity, these powders were expected to have low particle den-
sities and small aerodynamic diameters suitable for inhalation.
Indeed, the powders taken in a disposable tip were dispersed easily
by releasing air compressed in a syringe, suggesting that they are suit-
able for use as inhalable formulations.
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Figure 3. Anti-tumor Effect of VEGF-siRNA Dry
Powder in B16F10 Lung Metastasis Model
Mice with lung metastases were treated with VEGF-
siRNA dry powder (n = 6), non-target siRNA dry powder
(n = 5), or PBS (n = 5) by intratracheal administration on
days 4 and 11. (A and B) The number of tumor nodules on
the lung surface was counted 18 days after injection of
B16F10 cells. Bars denote the median values. (C and D)
H&E-stained sections from each mouse treated with
VEGF-siRNA, non-target siRNA, or PBS were randomly
selected, and the ratio of tumor/whole-lung tissue area
(%) was calculated using an image-analyzing system.
p was determined using the Wilcoxon rank-sum test.
*p < 0.05, **p < 0.01 between two groups. N.S., not
significant.
www.moleculartherapy.orgTo evaluate the in vitro inhalation performance of the VEGF-siRNA
and chitosan dry powder, the Anderson cascade impactor was used
(Figure 7). The powder reached the lower stages depending on the
pressure drop of the device, suggesting that the powder particles
were small enough to reach the lower airway, including alveoli.
Next, we calculated the output efﬁciency (OE) and ﬁne particle frac-
tion (FPF). As shown in Figure 8, OE exceeded 80% regardless of the
device. FPF3 and FPF5 increased with increased pressure drop in the
device. Even with Jethaler Single, FPF3 reached 50%, suggesting that
the powder could be inhaled by patients with weak inhalation
capacity.
DISCUSSION
In the present study, we demonstrated that a single intratracheal
administration of a novel VEGF-siRNA and chitosan dry powderMolecular Therapproduced by SFD reduced VEGF in both
BALF and lung tumor tissue in murine lung
metastasis models. Moreover, repeated intratra-
cheal administration of VEGF-siRNA dry pow-
der reduced the number of visible foci on the
lung surfaces and tumor area. Additionally,
the powder particles were shown to have inhal-
able characteristics in vitro with regard to both
their particle size and inhalation efﬁcacy.
The most notable ﬁnding in this study was that
even a single intratracheal administration of
VEGF-siRNA and chitosan dry powder pro-
duced by SFD suppressed gene expression in
lung tumor tissue. This effect was conﬁrmed
by the result that VEGF in BALF was reduced
to a similar level as that of mice without lung tu-
mors. SFD is a novel powderization technique
used to produce a highly porous low-density
powder, which is ideal for nucleic acids because
of its good dispersibility.11,17–19 The powders
produced by SFD are considered more suitable
for inhalation compared with those producedby conventional techniques. We previously demonstrated that intra-
tracheal administration of EGFP-siRNA and chitosan dry powder
produced by the supercritical CO2 technique reduced EGFP expres-
sion not only in the airways, but also inside metastatic lung tumor
tissue.7 However, the effect of intratracheal administration of siRNA
dry powders produced by SFD had not been elucidated. In the present
study, we demonstrated that a single intratracheal administration of a
novel siRNA dry powder produced by SFD could reduce gene expres-
sion in metastatic lung tumors.
We also clariﬁed that repeated intratracheal administration of VEGF-
siRNA and chitosan dry powder inhibited tumor growth in the lung.
Several previous studies also showed an anti-tumor effect of intratra-
cheal administration of RNA interference agents in murine lung
metastasis models. However, these RNA interference agents werey: Nucleic Acids Vol. 12 September 2018 701
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Figure 4. Toxicity of Intratracheal Administration of
siRNA Dry Powder
(A) Body-weight fluctuation in mice with lung metastases
treated with VEGF-siRNA dry powder, non-target siRNA
dry powder, or PBS (mean ± SE). There was no significant
difference in body weight between groups during the time
course (n = 5–6/group). (B–E) Representative histological
appearance of H&E-stained lung sections from mice
treated with VEGF-siRNA (B), non-target siRNA (C), PBS
(D), and bleomycin (E). The bleomycin group (intratracheal
injection of 2.5 mg/kg body weight) served as a positive
control. Scale bar, 100 mm.
Molecular Therapy: Nucleic Acidsinhaled using MDIs or nebulizers.8–10,20 While DPIs show several
beneﬁts compared with MDIs or nebulizers, little is known about in-
tratracheal administration of nucleic acids inhaled using DPIs.12,21,22
The present study is the ﬁrst that demonstrates a therapeutic effect of
inhaled siRNA dry powder using disease models.
Because nucleic acids are easily degraded in vivo, an appropriate
vector is required for their effective delivery to targeted cells. Viral
vectors,23,24 lipid vectors,25,26 and cationic polymers27,28 have been re-
ported as appropriate vectors for inhalable siRNA. Among them, we
focused on water-soluble chitosan because of its low toxicity. Indeed,
no remarkable toxicity such as body weight loss or histological
changes in the lungs were observed. Thus, we propose that chitosan
is an ideal vector for siRNA delivery.
The VEGF-siRNA and chitosan dry powder is highly porous, a unique
property among SFD powders. Its in vitro inhalation performance was
very high even with Jethaler Single, which has the lowest pressure drop,702 Molecular Therapy: Nucleic Acids Vol. 12 September 2018suggesting that the powder is suitable for inhala-
tion. We did not determine the mass median
aerodynamic diameter (MMAD) of the powder
because the log-probability plot, which is
commonly applied to determine MMAD of in-
halable powders, yielded a curve instead of a
straight line (data not shown). We consider that
some of the VEGF-siRNAand chitosan dry pow-
der particles were broken into tiny fragments in
the devices by the air turbulence, which would
improve particle delivery deep into the lungs.
Our study has certain limitations. First, the
detailed mechanism by which the siRNA dry
powder reached the inside of lung tumors has
not been determined. We speculate that there
could be pathways operating between lung
tumors and the airways. Another potential
explanation is that intratracheal administration
of siRNA dry powder could reduce gene expres-
sion not only in lung tumor, but also in other
cell types, including bronchial and alveolarepithelial cells.7 Thus, VEGF-siRNAmay indirectly suppress both in-
tratumor VEGF expression and tumor growth by suppressing VEGF
gene expression in other surrounding airway cells. Second, though we
showed a therapeutic effect of intratracheal administration of siRNA
dry powder inmurine lungmetastasis models, the effect of this system
on primary lung cancer is unknown. Finally, because the drug depo-
sition fractions in the upper airway are higher with DPIs than with
MDIs in humans,29 higher doses of dry powders may be required
to translate the present murine ﬁndings into human clinical practice.
In addition, sufﬁcient lung function will be necessary to enable inha-
lation of dry powder in humans; thus, patients with impaired lung
function may not be able to use this device.
In summary, we demonstrated that a single intratracheal administra-
tion of a novel VEGF-siRNA and chitosan dry powder produced by
SFD suppressed gene expression in lung tumors. Moreover, the
repeated administration of the dry powder inhibited tumor growth
in the lung. Intratracheal administration of siRNA and chitosan dry
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Figure 5. Anti-tumor Effect of VEGF-siRNA Dry
Powder in LLC Lung Metastasis Model
Mice with lung metastases were treated with an intra-
tracheal administration of VEGF-siRNA dry powder or
non-target siRNA on days 4, 8, and 11 (n = 4/group).
(A and B) The number of tumor nodules on the lung sur-
face was counted 14 days after injection of LLC cells.
Bars denote the median values. (C and D) H&E-stained
sections from each mouse treated with VEGF-siRNA or
non-target siRNA were randomly selected; the ratio of
tumor/whole-lung tissue area (%) was calculated using an
image analyzing system. p was determined using the
Wilcoxon rank-sum test. *p < 0.05 between two groups.
www.moleculartherapy.orgpowder could be a novel therapeutic strategy for lung cancer due to its
sequence speciﬁcity and high gene-silencing effect.
MATERIALS AND METHODS
Each experiment was performed two or three times. Reproducible and
representative data are shown as results.
Mice and Materials
Female C57BL/6 mice (8 to10 weeks old) were purchased from Japan
SLC (Hamamatsu, Japan). Animals were maintained according
to guidelines for the ethical use of animals in research at Hirosh-
ima University. VEGF-siRNA (sense strand, 50-CGAUGAAGCCCU
GGAGUGCTT-30; antisense strand, 50-GCACUCCAGGGCUUCMolecular TherapyAUCGTT-30) and non-target siRNA (sense
strand, 50-UACUAUUCGACACGCGAAG
TT-30; antisense strand, 50-CUUCGCGUGUC
GAAUAGUATT-30) were purchased from
Hokkaido System Science (Sapporo, Japan).
Chitosan (molecular weight [MW] 2,000–
5,000, water-soluble; Wako Pure Chemical
Industries, Osaka, Japan), D-(-)-mannitol
(Wako Pure Chemical Industries) and
L-leucine (Sigma-Aldrich, St. Louis, MO,
USA) were used as a non-viral vector and
excipient, respectively.
Cell Line
B16F10 melanoma cells and LLC cells were
purchased from ATCC (Manassas, VA, USA).
These cells were cultured in DMEM (Gibco,
Grand Island, NY, USA) containing 10% fetal
calf serum and 1% penicillin and streptomycin.
All cells were cultured at 37C in a humidiﬁed
atmosphere with 5% CO2.
Preparation of siRNA and Chitosan Dry
Powder using SFD
A schematic diagram of the SFD technique is
shown in Figure S1. A siRNA and chitosandry powder was prepared as previously described.12 A total quantity
of 66.5 mg of materials (composition ratio, siRNA 2%, chitosan 10%,
mannitol 22%, L-leucine 66%) was dissolved in 5.0 mL of ultra-pure
water. The solution was delivered at a rate of 5 mL/min and atomized
at an air pressure of 150 kPa using a two-ﬂuid nozzle for a spray dryer
(SD-1000, Tokyo Rikakikai, Tokyo, Japan) placed approximately
10 cm above liquid nitrogen. Following atomization, the liquid nitro-
gen, including frozen droplets, was transferred to a freeze dryer
(FDU-2100/DRC-1000; Tokyo Rikakikai) and pre-cooled at a shelf
temperature of 40C. After evaporation of the liquid nitrogen,
frozen droplets were dried at a pressure of less than 2 Pa, while the
shelf temperature was gradually increased from 40C to 10C
over a period of 24 hr.: Nucleic Acids Vol. 12 September 2018 703
Figure 6. Scanning Electron Micrographs of Spray-
Freeze-Dried Powders
(A and B) Powders with VEGF-siRNA and (C and D)
powders with non-target siRNA.
Molecular Therapy: Nucleic AcidsIntratracheal Administration of siRNA and Chitosan Dry Powder
Intratracheal administration of siRNA and chitosan dry powder was
conducted as previously described.7 In brief, a 22G catheter was con-
nected to a disposable yellow tip, and 0.5 mg siRNA and chitosan
powder or 10 mL PBS was placed into the yellow tip (Figure S2A).
Next, a three-way stopcock and 1 mL syringe containing 0.3 mL of
air was connected to the yellow tip. Mice were anesthetized and orally
intubated with the 22-gauge catheter connected to the yellow tip,
three-way stopcock, and 1 mL syringe. By pushing the 1-mL syringe
and opening the three-way stopcock, dry powder was dispersed into
the trachea (Figures S2B and S2C). To conﬁrm no visible powder
remained in the tip, air was instilled into the connected yellow tip
several times.
Verification of Knockdown Effect by VEGF-siRNA In Vitro
B16F10 cells or LLC cells (0.3  105/well) were plated on 24-well
plates; 24 hr after plating, B16F10 cells or LLC cells were transfected
with VEGF-siRNA (10 nM), non-target siRNA (10 nM), or transfec-
tion reagent alone. A lipofectamine RNAiMAX transfection reagent
(Invitrogen, Carlsbad, CA, USA) was used as a transfection reagent
in each group. The cell culture supernatant ﬂuid and the cells were
collected 48 hr after transfection.
BALF Analysis
B16F10 cells (2.0  105) or LLC (3.0  105) cells were injected intra-
venously into mice through the tail vein. The siRNA dry powder was
intratracheally administered 16 days (B16F10) or 12 days (LLC) after
cell injection. Two days after administration, a bronchoalveolar704 Molecular Therapy: Nucleic Acids Vol. 12 September 2018lavage was performed using 1.5 mL PBS, and
BALF was obtained from each mouse.
Quantification of VEGF Protein
Total VEGF protein in culture supernatant ﬂuid
or BALF was measured using a Mouse VEGF
Quantikine ELISA kit (R&D Systems, Minneap-
olis, MN, USA) following the manufacturer’s
instructions.
Real-Time qPCR
Total RNA was isolated from cultured cells
using an RNeasy Mini Kit (QIAGEN, Hilden,
Germany). The reverse transcription reaction
was performed using a High Capacity RNA-
to-cDNA Kit (Applied Biosystems, Foster City,
CA, USA) following the manufacturer’s instruc-
tions. Real-time qPCR was performed using a
7500 Fast Real-Time PCR system (Applied Bio-systems) for evaluation of mouse VEGF-A expression (Applied
Biosystems; assay ID, Mm00437306_m1), with beta-actin (Applied
Biosystems; assay ID, Mm02619580_g1) used as a control house-
keeping gene.
Evaluation of Anti-tumor Effect In Vivo
B16F10 cells (2.0  105) or LLC (3.0  105) cells were injected intra-
venously into mice through the tail vein. VEGF-siRNA or non-target-
siRNA were intratracheally administered on days 4 and 11 (B16F10)
or on days 4, 8, and 11 (LLC). Mice were sacriﬁced 18 days (B16F10)
or 14 days (LLC) after injection, and the number of visible foci on the
lung surface was manually counted.
Lung Histology
Mouse lung tissues were ﬁxed in 10% formalin and embedded in
parafﬁn. After sectioning 5-mm-thick slices, tissue was stained with
H&E or used for immunohistochemical staining. To estimate the
tumor burden, three randomly selected H&E sections were used to
calculate tumor area using an image analyzing system (BZ Analyzer
2, Keyence, Osaka, Japan).
Immunohistochemistry of VEGF-A
Mouse lung sections were incubated with rabbit polyclonal antibody
against mouse VEGF-A (Abcam, Cambridge, UK) at 4C overnight.
The immunoreaction was ampliﬁed using a VECTASTAIN ABC kit
(Vector Laboratories, Burlingame, CA,USA) and visualized after incu-
bation with a 3,3-diaminobenzidine solution acting as a chromogen.
Sections were then counterstained with hematoxylin and dehydrated.
Figure 7. In Vitro Deposition Patterns of VEGF-siRNA and Chitosan Dry
Powders
The powder was put in Jethaler single (white square), dual (gray square), and reverse
(black square), and inhalation performance was evaluated as described in the
Materials and Methods section. According to the cut-off diameters in each stage,
stages 1 and 2 were classified as upper airway, stages 3 and 4 were classified as
central airway, and stages 5–7 were classified as lower airway. Mean ± SD (n = 3).
Figure 8. Output Efficiency and Fine Particle Fractions of VEGF-siRNA and
Chitosan Dry Powders
The powder was placed in Jethaler single (white square), dual (gray square), and
reverse (black square), and inhalation efficiency was determined as described in the
Materials and Methods section. Mean ± SD (n = 3).
www.moleculartherapy.orgMorphological Analysis of the SFD Powders by Scanning
Electron Microscopy
Small amounts of powder samples were placed in a disposable tip con-
nected to a 1-mL disposable syringe with a three-way stopcock. The
powders were manually dispersed on a specimen mount with dou-
ble-sided tape by opening the three-way stopcock to release air com-
pressed in the syringe and coated with platinum by a sputter coater
(JFC-1600, JOEL, Tokyo, Japan). The morphology of the dry powders
was examined by scanning electron microscopy (JSM-6060, JEOL).
In Vitro Inhalation Characteristics of VEGF-siRNA and Chitosan
Dry Powders
The in vitro inhalation characteristics of the prepared dry powders
were evaluated using an eight-stage Andersen cascade impactor
(AN-200; SIBATA SCIENTIFIC TECHNOLOGY, Saitama, Japan).
The cut-off diameters in stages 1 to 7 and ﬁlter were 11, 7.0, 4.7,
3.3, 2.1, 1.1, 0.65, and 0.43 mm, respectively. We prepared VEGF-
siRNA and chitosan dry powder with 1% sodium ﬂuorescein (FlNa)
to quantify the amount of the powder recovered at each stage. The
shape of the particles observed by scanning electron microscopy
was not affected by the addition of FlNa. To prevent the dry powder
from re-bounding off the plates and re-entering the air stream, the
metal plates for the stages were coated with a thin layer of glycerin.
After setting a no. 2 hydroxypropyl methylcellulose (HPMC) hard
capsule (Shionogi Qualicaps Nara, Japan) containing 1 mg of the
dry powder in an inhaler (Jethaler Single, Dual, and Reverse; Hitachi
Automotive Systems, Isesaki, Japan), inspiration at a ﬂow rate of
28.3 L/min and for a ﬂow time of 5 s was carried out using a vacuum
pump. The pressure drops at a constant ﬂow rate (28.3 L/min) of the
devices were set at 1.0, 5.1, and 8.7 kPa, and the peak ﬂow rates that
normal subjects could achieve with the devices were 34–115, 15–52,
and 12–40 L/min, respectively.30 After inspiration, the dry powder
deposited in each part (capsule, device, throat, stages, and ﬁlter)
was washed out using 10 mL of PBS, and the concentration of FlNa
was determined using a ﬂuorescence microplate reader (EnSpire;
PerkinElmer Japan, Yokohama, Japan).OE, FPF3, and FPF5 were calculated by the following equations:
OEð%Þ= amounts in throat and lower parts=
amounts in total parts 100 (Equation 1)
FPF3ð%Þ= amounts in stage 3 and lower parts=
amounts in throat and lower parts100 (Equation 2)
FPF5ð%Þ= amounts in stage 5 and lower parts=
amounts in throat and lower parts 100 (Equation 3)
OE is the emission potential from the capsule and device, while FPF3
and FPF5 refer to the potential for delivery into the lung and deep
lung, respectively.Statistical Data Analysis
Statistical analyses were performed using the Wilcoxon rank-sum
test. p values less than 0.05 were considered statistically signiﬁcant.
Analyses were performed using JMP pro 12 software (SAS Institute,
Cary, NC, USA).
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